A Study of SSS17 in Healthy Subjects

NCT ID: NCT04317833

Last Updated: 2020-03-23

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 65 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-05-01
• Study Completion Date: 2021-12-31

Brief Summary

This is a first-in-human, Phase 1, single-center, randomized, single-blind, placebo-controlled, single dose-escalation study to evaluate the safety, tolerability, PK, PD of SSS17 following oral administration in healthy subjects. Approximately 65 subjects (53 receiving active drug and 12 receiving placebo) will participate in this study.

Detailed Description

The study will enroll healthy volunteers from a single academic medical center in China. All participants will be informed about the study and potential risks and required to provide written informed consent prior to undergoing study-related procedures.

The improved Fibonacci dose escalation design will be implemented. The protocol specifies 10 mg, oral, one time for the first cohort without placebo control. Successive cohorts will be given doses up to 540 mg with placebo parallel control. Only no observation meets the criteria under stop rules, dose will escalate to the next higher level.

The study will be divided into 2 stages: 1st period (fast) and 2nd period(fed).

First period (fast): Subjects will be allocated 1:4 to receive placebo or SSS17, which will be administered by oral route. At each dose, tolerability, safety, PK and PD characteristics will be investigated.

Second period (fed): in order to investigate the effects of food on PK and PD of SSS17. Subjects in one cohort will be administered again after meal on Day15. The accurate dose will be adjusted according to the findings in 1st period (fast)

Conditions

Anemia in Chronic Kidney Diseases

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Dose Escalation SSS17

Escalating doses of SSS17; single dose administration; different dosage forms (redosing of the SSS17 in one cohort with food on Day15)

Group Type: EXPERIMENTAL

SSS17

Intervention Type: DRUG

SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxia-inducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.

Escalation matching Placebo

Escalating doses of matching placebo; single dose administration; different dosage forms (redosing of matching placebo in one cohort with food on Day15)

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

matched placebo

Interventions

SSS17

SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxia-inducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.

Intervention Type: DRUG

Placebo

matched placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Body weight≥50 for male or ≥45 for female, and BMI between 19.0-26.0 kg/m2
• Good general health as determined by the investigator based on medical history, physical examination, vital signs, 12-lead ECG, clinical laboratory tests and B-type ultrasound test.
• Participants of reproductive potential must agree to utilize reliable methods of contraception from screening to 6 months after the last administration of the study intervention. No plan for sperm (or egg) donation or pregnancy.
• Understand and sign the informed consent.
• Ability to understand and follow study-related instruction

Exclusion Criteria

• A known allergy to any component of the SSS17 formulation, or allergy history of two kinds of drugs or food
• Medical history or conditions of digestive system.
• Female volunteers who are pregnant, menstrual, lactating or menopause with hormone therapy.
• Eyes diseases, including diabetic retinopathy, age-related macular degeneration.
• Vascular anomalies.
• Drug, alcohol or nicotine addiction.
• Blood donation or bleeding (more than 200 ml). Experience of treatment with EPO or blood transfusion.
• Any findings from the medical examination (including medical history, physical examination, vital signs, laboratory tests and ECG) deviating from normal and deemed by the investigator to be of clinical relevance
• Abnormal results in test of TIBC, serum iron or ferritin
• Acute diseases before administration.
• Other situations that the researcher believes may affect validity judgment or are not suitable for participation

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Shenyang Sunshine Pharmaceutical Co., LTD.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Shanghai Public Health Clinical Center

Shanghai, Shanghai Municipality, China

Countries

China

Central Contacts

Hongzhou Lu, Ph.D

Role: CONTACT

jigouban@126.com

(021)37990333-5278

Facility Contacts

Hongzhou Lu

Role: primary

Other Identifiers

SYSS-SSS17-UND-I-01

Identifier Type: -

Identifier Source: org_study_id